# EXTRACÇÃO PERCUTÂNEA DE ELÉCTRODOS: INDICAÇÕES, TÉCNICAS E RESULTADOS

#### **BRUNO TERENO VALENTE**


Centro Hospitalar de Lisboa Central, EPE - Hospital de Santa Marta / Serviço de Cardiologia





### **DISPOSITIVOS IMPLANTADOS EU**


CRT-D - Units per million inhabitants





### **DISPOSITIVOS IMPLANTADOS EU**

#### Defibrillators - Units per million inhabitants





### **DISPOSITIVOS IMPLANTADOS**

TODAY IN EUROPE IT IS ESTIMATED THAT AROUND 290,000 PACEMAKERS OF VARIOUS TYPES ARE IMPLANTED EACH YEAR, WITH 50% OF THESE BEING IMPLANTED TO TREAT DISTURBANCES OF SINUS NODE FUNCTION AND THE REMAINDER BECAUSE OF VARIOUS DEGREES OF IMPAIRMENT OF THE ATRIOVENTRICULAR CONDUCTION.





### TERMINOLOGIA NA REMOÇÃO DE EC

LEAD REMOVAL → REMOÇÃO DE EC´S DE PMD OU DESFIBRILADOR UTILIZANDO QUALQUER TÉCNICA

LEAD EXPLANT → TÉCNICAS SIMPLES DE TRAÇÃO (<1 A)

LEAD EXTRACTION → REMOÇÃO REQUER O AUXÍLIO DE EQUIPAMENTOS ESPECIALIZADOS



### INDICAÇÕES PARA REMOÇÃO DE EC

## Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management

This document was endorsed by the American Heart Association (AHA).

Bruce L. Wilkoff, MD, FHRS,\* Charles J. Love, MD, FHRS,† Charles L. Byrd, MD,‡ Maria Grazia Bongiorni, MD,§ Roger G. Carrillo, MD, FHRS,¶ George H. Crossley, III, MD, FHRS,¶ Laurence M. Epstein, MD,# Richard A. Friedman, MD, MBA, FHRS,\*\* Charles E. H. Kennergren, MD, PhD, FHRS,†† Przemyslaw Mitkowski, MD,‡‡ Raymond H. M. Schaerf, MD, FHRS,§§ Oussama M. Wazni, MD\*



### INDICAÇÕES PARA REMOÇÃO

A REMOÇÃO DE SISTEMA DCEI DEVE SER APENAS CONSIDERADA SE:


- BENEFICIO JUSTIFIQUE O RISCO ASSOCIADO AO PROCEDIMENTO
  - CARACTERÍSTICAS DE CADA DOENTE
  - EXPERIÊNCIA DO OPERADOR
  - TÉCNICA UTILIZADA (??)



### INDICAÇOES PARA REMOÇÃO

- INFECÇÃO (~70%; 28% (S); 42% (L)<sup>1</sup>)
- DOR CRÓNICA
- TROMBOSE / ESTENOSE VENOSA
- REMOÇÃO:
  - ELECTRODOS FUNCIONANTES
  - ELECTRODOS DISFUNCIONANTES









CURRENT PRACTICE IN TRANSVENOUS LEAD EXTRACTION: A EUROPEAN HEART RHYTHM ASSOCIATION EP NETWORK
SURVEY.
MARIA GRAZIA BONGIORNI ET AL BY THE SCIENTIFIC INITIATIVE COMMITTEE, EUROPEAN HEART RHYTHM ASSOCIATION

### **AUMENTO DAS INFECÇÕES**

- DOENTES COM MAIS COMORBILIDADES
- DISPOSITIVOS QUE REQUEREM MAIS EC / PTS
- UPGRADING DE DISPOSITIVOS + FREQUÊNTE
- OPERADORES MENOS EXPERIENTES



### REMOÇÃO - INFECÇÃO

#### Infection

#### Class I

- 1. Complete device and lead removal is recommended in all patients with definite CIED system infection, as evidenced by valvular endocarditis, lead endocarditis or sepsis. (Level of evidence: B)
- 2. Complete device and lead removal is recommended in all patients with CIED pocket infection as evidenced by pocket abscess, device erosion, skin adherence, or chronic draining sinus without clinically evident involvement of the transvenous portion of the lead system. (Level of evidence: B)
- 3. Complete device and lead removal is recommended in all patients with valvular endocarditis without definite involvement of the lead(s) and/or device. (Level of evidence: B)
- 4. Complete device and lead removal is recommended in patients with occult gram-positive bacteremia (not contaminant). (Level of evidence: B)

#### Class IIa


1. Complete device and lead removal is reasonable in patients with persistent occult gram-negative bacteremia. (Level of evidence: B)

#### Class III

- 1. CIED removal is not indicated for a superficial or incisional infection without involvement of the device and/or leads (Level of evidence: C)
- 2. CIED removal is not indicated to treat chronic bacteremia due to a source other than the CIED, when long-term suppressive antibiotics are required. (Level of evidence: C)



### REMOÇÃO - TROMBOSE / ESTENOSE



#### Thrombosis or Venous Stenosis

#### Class I

- 1. Lead removal is recommended in patients with clinically significant thromboem bolic events associated with thrombus on a lead or a lead fragment. (Level of evidence: C)
- 2. Lead removal is recommended in patients with bilateral subclavian vein or SVC occlusion precluding implantation of a needed transvenous lead. (Level of evidence: C)
- 3. Lead removal is recommended in patients with planned stent deployment in a vein already containing a transvenous lead, to avoid entrapment of the lead. (Level of evidence: C)
- 4. Lead removal is recommended in patients with superior vena cava stenosis or occlusion with limiting symptoms. (Level of evidence: C)
- 5. Lead removal is recommended in patients with ipsilateral venous occlusion preventing access to the venous circulation for required placement of an additional lead when there is a contraindication for using the contralateral side (e.g. contralateral AV fistula, shunt or vascular access port, mastectomy). (Level of evidence: C)

#### Class IIa

1. Lead removal is reasonable in patients with ipsilateral venous occlusion preventing access to the venous circulation for required placement of an additional lead, when there is no contraindication for using the contralateral side. (Level of evidence C)



### REMOÇÃO - DOR CRÓNICA

#### Chronic Pain

#### Class IIa

1. Device and/or lead removal is reasonable in patients with severe chronic pain, at the device or lead insertion site, that causes significant discomfort for the patient, is not manageable by medical or surgical techniques and for which there is no acceptable alternative. (Level of evidence: C)



### REMOÇÃO – EC FUNCIONANTES

#### **Functional Leads**

#### Class I

- 1. Lead removal is recommended in patients with life threatening arrhythmias secondary to retained leads. (Level of evidence: B)
- 2. Lead removal is recommended in patients with leads that, due to their design or their failure, may pose an immediate threat to the patients if left in place. (e.g. Telectronics ACCUFIX J wire fracture with protrusion). (Level of evidence: B)
- 3. Lead removal is recommended in patients with leads that interfere with the operation of implanted cardiac devices. (Level of evidence: B)
- 4. Lead removal is recommended in patients with leads that interfere with the treatment of a malignancy (radiation/reconstructive surgery). (Level of evidence: C)

#### Class IIb

- 1. Lead removal may be considered in patients with an abandoned functional lead that poses a risk of interference with the operation of the active CIED system. (Level of evidence: C)
- 2. Lead removal may be considered in patients with functioning leads that due to their design or their failure pose a potential future threat to the patient if left in place. (e.g. Telectronics ACCUFIX without protrusion) (Level of evidence: C)
- 3. Lead removal may be considered in patients with leads that are functional but not being used. (i.e. RV pacing lead after upgrade to ICD) (Level of evidence: C)
- 4. Lead removal may be considered in patients who require specific imaging techniques (e.g. MRI) that can not be imaged due to the presence of the CIED system for which there is no other available imaging alternative for the diagnosis. (Level of evidence: C)
- 5. Lead removal may be considered in patients in order to permit the implantation of an MRI conditional CIED system. (Level of

#### Class III

- 1. Lead removal is not indicated in patients with functional but redundant leads if patients have a life expectancy of less than one year. (Level of evidence: C)
- 2. Lead removal is not indicated in patients with known anomalous placement of leads through structures other than normal venous and cardiac structures, (e.g. subclavian artery, aorta, pleura, atrial or ventricular wall or mediastinum) or through a systemic venous atrium or systemic ventricle. Additional techniques including surgical backup may be used if the clinical scenario is compelling. (Level of evidence: C)



### REMOÇÃO – EC DISFUNCIONANTES

-MALFUNCTION ≈ 2.5 %

-1.65-20% ANNUAL ICD LEAD FAILURE BASED ON AGE 1,2

1 HAUSER, ROBERT ET AL. THE INCRESING HAZARD OF SPRING FIDELIS IMPLANTABLE CARDIOVERTER-DEFIBRILATOR LEAD FAILURE, HEART RHYTHM, VOL 6, NO5, MAY 2009 2 KLEEMAN THOMAS, ET AL. ANNUAL RATE OF TRANSVENOUS DEFIBRILATION LEAD DEFECT IN IMPLANTABLE-DEFIBRILATORS OVER A PERIOD OF >10 YEARS. CIRCULATION 2007, 115:2474-2490



### EXTRACÇÃO – EC DISFUNCIONANTES

#### Non Functional Leads

#### Class I


- 1. Lead removal is recommended in patients with life threatening arrhythmias secondary to retained leads or lead fragments. (Level of evidence: B)
- 2. Lead removal is recommended in patients with leads that, due to their design or their failure, may pose an immediate threat to the patients if left in place. (e.g. Telectronics ACCUFIX J wire fracture with protrusion) (Level of evidence: B)
- 3. Lead removal is recommended in patients with leads that interfere with the operation of implanted cardiac devices. (Level of evidence: B)
- 4. Lead removal is recommended in patients with leads that interfere with the treatment of a malignancy (radiation/reconstructive surgery). (Level of evidence: C)

#### Class IIa

- 1. Lead removal is reasonable in patients with leads that due to their design or their failure pose a threat to the patient, that is not immediate or imminent if left in place. (e.g. Telectronics ACCUFIX without protrusion) (Level of evidence C)
- 2. Lead removal is reasonable in patients if a CIED implantation would require more than 4 leads on one side or more than 5 leads through the SVC. (Level of evidence C)
- 3. Lead removal is reasonable in patients that require specific imaging techniques (e.g. MRI) and can not be imaged due to the presence of the CIED system for which there is no other available imaging alternative for the diagnosis. (Level of evidence: C) Class IIb
  - 1. Lead removal may be considered at the time of an indicated CIED procedure, in patients with non-functional leads, if contraindications are absent. (Level of evidence C)
- 2. Lead removal may be considered in order to permit the implantation of an MRI conditional CIED system. (Level of evidence: C) Class III
  - 1. Lead removal is not indicated in patients with non-functional leads if patients have a life expectancy of less than one year. (Level of evidence C)
  - 2. Lead removal is not indicated in patients with known anomalous placement of leads through structures other than normal venous and cardiac structures, (e.g. subclavian artery, aorta, pleura, atrial or ventricular wall or mediastinum) or through a systemic venous atrium or systemic ventricle. Additional techniques including surgical backup may be used if the clinical scenario is compelling. (Level of evidence: C)



### TÉCNICAS DE EXTRACÇÃO DE EC





### PERCUTÂNEA vs CIRÚRGICA

Table 24 Cardiac device-related infective endocarditis (CDRIE): treatment and prevention

Recommendations: IE on pacemakers and implantable defibrillators	Classa	Level
A - PRINCIPLES OF TREATMENT:		
Prolonged antibiotic therapy and device removal are recommended in definite CDRIE	1	В
Device removal should be considered when CDRIE is suspected on the basis of occult infection without other apparent source of infection	lla	С
In patients with native or prosthetic valve endocarditis and an intracardiac device with no evidence of associated device infection, device extraction may be considered	llb	С
B - MODE OF DEVICE REMOVAL:		
Percutaneous extraction is recommended in most patients with CDRIE, even those with large (> 10 mm) vegetations	- 1	В
Surgical extraction should be considered if percutaneous extraction is incomplete or impossible or when there is associated severe destructive tricuspid IE	lla	С
Surgical extraction may be considered in patients with very large (> 25 mm) vegetations	llb	С
C - REIMPLANTATION:		
After device extraction, reassessment of the need for reimplantation is recommended	1	В
When indicated, reimplantation should be postponed if possible to allow a few days or weeks of antibiotic therapy	lla	В
Temporary pacing is not recommended	111	С
D - PROPHYLAXIS	to a	
Routine antibiotic prophylaxis is recommended before device implantation	1	В

<sup>&</sup>lt;sup>a</sup>Class of recommendation.



Level of evidence.

### TÉCNICAS DE EXTRACÇÃO DE EC

**MECHANICAL SHEATHS (POLYPROPYLENE)** 







### TÉCNICAS DE EXTRACÇÃO DE EC

#### **POWERED:**

ROTATING THREADED TIP (EVOLUTION)
LASER SHEATHS
ELECTROSURGICAL SHEATHS (RF)







### TAXA DE SUCESSO E COMPLICAÇÕES

Journal of the American College of Cardiology © 1999 by the American College of Cardiology Published by Elsevier Science Inc. Vol. 33, No. 6, 1999 ISSN 0735-1097/99/\$20.00 PII S0735-1097(99)00074-1

Pacemaker Lead Extraction With the Laser Sheath: Results of the Pacing Lead Extraction With the Excimer Sheath (PLEXES) Trial

Bruce L. Wilkoff, MD, FACC,\* Charles L. Byrd, MD, FACC,† Charles J. Love, MD, FACC,‡ David L. Hayes, MD, FACC,§ T. Duncan Sellers, MD, FACC,∥ Raymond Schaerf, MD,¶ Victor Parsonnet, MD, FACC,# Laurence M. Epstein, MD, FACC,\*\* Robert A. Sorrentino, MD,†† Christopher Reiser, PHD‡‡

Cleveland, Ohio; Fort Lauderdale, Florida; Columbus, Ohio; Rochester, Minnesota; Colorado Springs, Colorado; Burbank, California; Newark, New Jersey; Boston, Massachusetts, and Durham, North Carolina

RESULTS (301 pts): COMPLETE LEAD REMOVAL RATE WAS 94% (L) VS 64% (M) POTENTIALLY LIFE-THREATENING COMPLICATIONS OCCURRED IN NONE OF THE NONLASER AND THREE OF THE LASER PATIENTS, INCLUDING ONE DEATH

CONCLUSIONS: LASER-ASSISTED PACEMAKER LEAD EXTRACTION HAS SIGNIFICANT CLINICAL ADVANTAGES OVER EXTRACTION WITHOUT LASER TOOLS AND IS ASSOCIATED WITH SIGNIFICANT RISKS.



### INSUCESSOS DE EXTRACÇÃO

CEC
INTERNAMENTO PROLONGADO
CIRURGIA CARDÍACA EM DOENTE INFECTADO



















MECHANICAL EXTRACTION SHEATH


POWERED EXTRACTION SHEATH LASER, RF, THREADED









### TÉCNICA DE PISA - JUGULAR




























#### INTERNAL JUGULAR APPROACH





#### **RESULTS**

**JANUARY 1997-JUNE 2011 1711 PATIENTS - 3092 LEADS** 



**TOTAL REMOVAL 98%** 

■ NOT APPLICABLE

■ FALIURE

■ PARTIAL REMOVAL

TOTAL REMOVAL



MAJOR COMPLICATIONS 10 PTS (0.58%)

JANUARY 1977 – JUNE 2011 1711 PATIENTS – 3092 LEADS

6F / 4M (MEAN AGE 73.4YRS) (RANGE 65-85)


CARDIAC TAMPONADE 9
(FATAL) 2

HEMOTHORAX 1 (FATAL) 1

DEATHS 3 / 1711PTS (0.17%)

NO SVC TEARS







### **REGISTO ELECTRa**

### **EUR***Observational* Research Programme

**Protocol** 

**ELECTRa** 

(European Lead Extraction ConTRolled)
Registry

*September 19<sup>th</sup>, 2012* 

Study promoted by the European Society of Cardiology

Executive Committee:

Maria Grazia Bongiorni, Chair



### FIM

